Related Posts

• Patent Reform Blocked, Epix Deal Expanded, Repligen Suit Settled, & More Life Sciences News
• Caliper and Anticancer Bench Attorneys to End Patent Suit, Strike Cross Licensing Deal
• 3Com Wins $45 Million in Patent Suit Against Taiwanese Chipmaker
• No Patent Reform: Court Blocks New Patent Rules
• Codon Devices Settles Patent Suit

Legal, Patents, Biotech

Repligen, BMS Settle Patent Suit

Rebecca Zacks 4/8/08 4:29 pm

Repligen (NASDAQ: RGEN) of Waltham, MA, will collect $5 million from Bristol-Myers Squibb (NYSE: BMY) as part of the settlement, announced today, of a patent suit that the Massachusetts firm filed in 2006. Repligen will also collect royalties on BMS’s arthritis drug, Orencia, which Repligen and co-plaintiff the University of Michigan charged violated a patent owned by the university and the Navy and licensed exclusively to Repligen. All told, the royalties could be worth up to $117 million, according to a report in Mass High Tech.

Permalink | Share |

Why is this story so short? Because it's a news brief from our News Xpress section, which brings you quick takes on the latest Boston-area biz/tech news as it unfolds throughout the day.

Where do I find more in-depth news and analysis about the business of technology in the Boston area? We've got plenty of that right on our home page and in our archives.

Who the heck are the Xconomists mentioned on your homepage? They're an elite group of movers and shakers in the local tech scene who've generously agreed to share their insights and opinions with Xconomy's readers. Here's a complete list of them; to read their posts, have a look here and here.

Come to think of it, what does "Xconomy" mean in the first place? Xconomy is a word we made up to evoke the exponential economy—the realm of business and innovation characterized by exponential technological growth and responsible for an increasing share of productivity and overall economic growth. (Not everybody likes the name, by the way. We're okay with that.) We're a small group of professional journalists dedicated to bringing you the most important news about New England's role in the exponential economy. More on our mission and team here.